Effect of maximum inhalation flow and inhaled volume on formoterol drug deposition in-vitro from an Easyhaler® dry powder inhaler

Abadelah, Mohamad; Hazim, Firisteh; Chrystyn, Henry; Bagherisadeghi, Golshan; Rahmoune, Hassan; Larhrib, Hassan

doi:10.1016/j.ejps.2017.03.035

Cited by 21 publications

(15 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The turbulence generated at high flow rates 60 and 90 L/min was able to generate sufficient shear forces between drug-drug particles. Such phenomenon would be able to enhance particle dispersion leading to the formation of smaller particle size (36) as shown in Fig. 3.…”

Section: Resultsmentioning

confidence: 99%

Study of the Emitted Dose After Two Separate Inhalations at Different Inhalation Flow Rates and Volumes and an Assessment of Aerodynamic Characteristics of Indacaterol Onbrez Breezhaler® 150 and 300 μg

et al. 2017

Self Cite

View full text Add to dashboard Cite

Abstract.Onbrez Breezhaler® is a low-resistance capsule-based device that was developed to deliver indacaterol maleate. The study was designed to investigate the effects of both maximum flow rate (MIF) and inhalation volume (Vin) on the dose emission of indacaterol 150 and 300 μg dose strengths after one and two inhalations using dose unit sampling apparatus (DUSA) as well as to study the aerodynamic characteristics of indacaterol Breezhaler® using the Andersen cascade impactor (ACI) at a different set of MIF and Vin. Indacaterol 150 and 300 μg contain equal amounts of lactose per carrier. However, 150 μg has the smallest carrier size. The particle size distribution (PSD) of indacaterol DPI formulations 150 and 300 μg showed that the density of fine particles increased with the increase of the primary pressure. For both strengths (150 μg and 300 μg), ED1 increased and ED2 decreased when the inhalation flow rate and inhaled volume increased. The reduction in ED1 and subsequent increase in ED2 was such that when the Vin is greater than 1 L, then 60 L/min could be regarded as the minimum MIF. The Breezhaler was effective in producing respirable particles with an MMAD ≤5 μm irrespective of the inhalation flow rate, but the mass fraction of particles with an aerodynamic diameter <3 μm is more pronounced between 60 and 90 L/min. The dose emission of indacaterol was comparable for both dose strengths 150 and 300 μg. These in vitro results suggest that a minimum MIF of 60 L/min is required during routine use of Onbrez Breezhaler®, and confirm the good practice to make two separate inhalations from the same dose.

show abstract

Section: Resultsmentioning

confidence: 99%

Study of the Emitted Dose After Two Separate Inhalations at Different Inhalation Flow Rates and Volumes and an Assessment of Aerodynamic Characteristics of Indacaterol Onbrez Breezhaler® 150 and 300 μg

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…For example, when PIF was studied on the Easyhaler (a relatively high-resistance device compared with the Symbicort Turbuhaler) in adult and paediatric patients with asthma, as well as adults with COPD, the 10th, 50th and 90th percentiles for PIF were 44.7 L min −1 , 61.1 L min −1 and 74.8 L min −1 [18], respectively. Further, the dosing has been shown to be consistent for PIF values of 28.3–74.8 L min −1 [31, 32]. (Fig.…”

Section: From Powder To Aerosolmentioning

confidence: 98%

Understanding Dry Powder Inhalers: Key Technical and Patient Preference Attributes

Levy¹,

Carroll

Alonso

et al. 2019

Adv Ther

View full text Add to dashboard Cite

Inhalable medications for patients with asthma and chronic obstructive pulmonary disease (COPD) can be confusing even for health care professionals because of the multitude of available devices each with different operating principles. Dry powder inhalers (DPI) are a valuable option for almost all of the patients with asthma or COPD. Based on recorded patient inspiratory profiles, the peak inspiratory flow requirement of 30 L min−1 of high-resistance devices does not usually pose any practical limitations for the patients. Suboptimal adherence and errors in device handling are common and require continuous checking and patient education in order to avoid these pitfalls of all inhalation therapy. The aim of this opinion paper is to describe the working principles of DPIs and to summarise their key properties in order to help prescribing the correct inhaler for each patient.Funding: Orion Pharma.

show abstract

“…In the other study comparing patient satisfaction with the use of Bufomix Easyhaler ® , patients who had previously used another pressure inhaler appreciated its easy preparation before inhalation and the ease of keeping it clean [ 21 ]. Also other studies confirm easy handling of Bufomix Easyhaler ® in the patients’ everyday life [ 4 , 11 , 13 , 22 – 24 ].…”

Section: Discussionmentioning

confidence: 57%

Evaluation of the Efficiency of Single-Inhaler Combination Therapy with Budesonide/Formoterol Fumarate in Patients with Bronchial Asthma in Daily Clinical Practice

Pirożyński

Hantulik²,

Almgren-Rachtan³

et al. 2017

Adv Ther

View full text Add to dashboard Cite

IntroductionThe effectiveness of single-inhaler budesonide/formoterol fumarate combination therapy for asthma has been previously shown for the original product. The aim of this nonrandomized, open-label, postauthorization efficacy study (PAES) real-life clinical assessment was to evaluate the clinical effectiveness of a second product (Bufomix Easyhaler®) in the daily clinical practice of asthma therapy.MethodsThis multicenter PAES was conducted by 220 unselected allergologists and pulmonologists who enrolled 2200 adult outpatients (age 49.8 ± 17.9 years) with asthma treated with Bufomix Easyhaler® for at least 14 days before enrolment. Asthma control was assessed during three subsequent visits with 8–12-week intervals on the basis of the Asthma Control Test (ACT). Adherence was assessed with the Medication Adherence Questionnaire. In addition, patient satisfaction with Bufomix Easyhaler® was scored, and adverse drug reactions were recorded.ResultsThe percentage of patients with well-controlled asthma or total control of asthma (ACT score 20-25 points) increased from 46.6% at the first visit to 90.8% at the third visit (p < 0.001). In addition, the percentage of patients with poor control of asthma (ACT score less than 15 points) decreased from 14.9% to 1.2% (p < 0.001). The adherence rate increased from 88% at the first visit to 95.3% at the third visit. Patient satisfaction with the use of this dry powder inhaler increased with the duration of its use. Only one adverse drug reaction was reported.ConclusionThe results obtained confirm the effectiveness of Bufomix Easyhaler® in the treatment of asthma in outpatient adults in daily clinical practice.FundingOrion Corporation

show abstract

Effect of maximum inhalation flow and inhaled volume on formoterol drug deposition in-vitro from an Easyhaler® dry powder inhaler

Cited by 21 publications

References 23 publications

Study of the Emitted Dose After Two Separate Inhalations at Different Inhalation Flow Rates and Volumes and an Assessment of Aerodynamic Characteristics of Indacaterol Onbrez Breezhaler® 150 and 300 μg

Study of the Emitted Dose After Two Separate Inhalations at Different Inhalation Flow Rates and Volumes and an Assessment of Aerodynamic Characteristics of Indacaterol Onbrez Breezhaler® 150 and 300 μg

Understanding Dry Powder Inhalers: Key Technical and Patient Preference Attributes

Evaluation of the Efficiency of Single-Inhaler Combination Therapy with Budesonide/Formoterol Fumarate in Patients with Bronchial Asthma in Daily Clinical Practice

Contact Info

Product

Resources

About